2-Amino-4-methoxy-5-(3-morpholinopropoxy)benzonitrile, 95.0%, 25g

tert-Butyl 4-((6-aminopyridin-3-yl)methyl)piperazine-1-carboxylate, 98%, 5g

1-Cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid, 98%, 5g

6-Bromo-N,N-dimethylpyridin-3-amine, 95.0%, 5g

3-(1H-1,2,3-Triazol-1-yl)aniline, 95%, 250mg

(2S,3R)-1-[(tert-Butoxy)carbonyl]-3-fluoropyrrolidine-2-carboxylic acid, 97%, 100mg

Phase contrast slide set with 10x and S40x PLPHi IOS infinity corrected objectives and phase contrast rings for 10x/S40x

2-Chloro-4-fluoro-3-methylbenzoic acid, 97.0%, 1g

2-((Tert-butoxycarbonyl)amino)-3-(thiazol-4-yl)propanoic acid, 98%, 1g

3-Methoxy-5-methylphenylamine, 95.0%, 5g

4'-Fluoro-3'-hydroxyacetophenone, 99.0%, 2.5g

1-(2-Amino-ethyl)-cyclohexanol, 500mg

N-Cinnamoyl-N-(2,3-xylyl)hydroxylamine>98.0%(HPLC)(N)5g